These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 24099103)

  • 21. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1.
    Barin F; Jourdain G; Brunet S; Ngo-Giang-Huong N; Weerawatgoompa S; Karnchanamayul W; Ariyadej S; Hansudewechakul R; Achalapong J; Yuthavisuthi P; Ngampiyaskul C; Bhakeecheep S; Hemwutthiphan C; Lallemant M;
    J Infect Dis; 2006 Jun; 193(11):1504-11. PubMed ID: 16652277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
    Ruprecht RM; Hofmann-Lehmann R; Smith-Franklin BA; Rasmussen RA; Liska V; Vlasak J; Xu W; Baba TW; Chenine AL; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Montefiori DC; McClure HM
    Transfus Clin Biol; 2001 Aug; 8(4):350-8. PubMed ID: 11642027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
    Gauduin MC; Parren PW; Weir R; Barbas CF; Burton DR; Koup RA
    Nat Med; 1997 Dec; 3(12):1389-93. PubMed ID: 9396610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.
    Klein F; Halper-Stromberg A; Horwitz JA; Gruell H; Scheid JF; Bournazos S; Mouquet H; Spatz LA; Diskin R; Abadir A; Zang T; Dorner M; Billerbeck E; Labitt RN; Gaebler C; Marcovecchio P; Incesu RB; Eisenreich TR; Bieniasz PD; Seaman MS; Bjorkman PJ; Ravetch JV; Ploss A; Nussenzweig MC
    Nature; 2012 Dec; 492(7427):118-22. PubMed ID: 23103874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies for prevention of mother-to-child transmission of HIV-1.
    Fouda GG; Moody MA; Permar SR
    Curr Opin HIV AIDS; 2015 May; 10(3):177-82. PubMed ID: 25700205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
    Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
    Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
    Front Immunol; 2020; 11():984. PubMed ID: 32582155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of HIV-1 neutralizing and binding antibodies in maternal-infant transmission in Thailand.
    Wieczorek L; Peachman K; Adams DJ; Barrows B; Molnar S; Schoen J; Dawson P; Bryant C; Chenine AL; Sanders-Buell E; Srithanaviboonchai K; Pathipvanich P; Michael NL; Robb ML; Tovanabutra S; Rao M; Polonis VR
    Virology; 2020 Sep; 548():152-159. PubMed ID: 32838936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The first 24 h: targeting the window of opportunity for antibody-mediated protection against HIV-1 transmission.
    Lewis GK
    Curr Opin HIV AIDS; 2016 Nov; 11(6):561-568. PubMed ID: 27559708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.
    Ashokkumar M; Aralaguppe SG; Tripathy SP; Hanna LE; Neogi U
    J Virol; 2018 May; 92(9):. PubMed ID: 29491151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
    Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-mediated prevention and treatment of HIV-1 infection.
    Gruell H; Klein F
    Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
    Mahomed S; Garrett N; Baxter C; Abdool Karim Q; Abdool Karim SS
    J Infect Dis; 2021 Feb; 223(3):370-380. PubMed ID: 32604408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
    Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
    PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing antibodies to HIV-1 induced by immunization.
    McCoy LE; Weiss RA
    J Exp Med; 2013 Feb; 210(2):209-23. PubMed ID: 23401570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes.
    Russell ES; Ojeda S; Fouda GG; Meshnick SR; Montefiori D; Permar SR; Swanstrom R
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):511-5. PubMed ID: 23075434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.